FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SHANGHAI and ATLANTA and NEW HAVEN, Conn., Jan. 05, 2026 (GLOBE ...

Researchers have designed a peptide that prevents the deadly misfolding of alpha-synuclein, the protein behind Parkinson’s and some dementias. In lab and animal tests, it stabilized the protein and ...

Parkinson’s disease is associated with the buildup of a particular brain protein that currently has no approved therapies addressing it. Novartis was among the companies pursuing this target, but its ...

In a recent study published in the Proceedings of the National Academy of Sciences, researchers assessed the capability of two small molecules of disintegrating alpha-synuclein fibrils. Parkinson's ...

PET tracers that illuminate α-synuclein in the brain have been hard to come by, but scientists may be getting closer. According to a study published August 3 in Cell, an 18F- tracer developed at Emory ...

Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by the aggregation of alpha-synuclein in the brain. Now, scientists have developed a radioligand that facilitates the ...

A small new trial published in the journal Nature Medicine describes what would be two firsts for Parkinson's disease, if they pan out: a diagnostic test and a potential immune-based treatment that ...

Phosphorylation of α-synuclein at serine 129 has long been used as a marker of synucleinopathy—p-S129syn accumulates in Lewy bodies, after all. But does this modification have a physiological function ...

Assessing pathological synuclein in simple skin biopsies can take the place of more invasive diagnostic procedures. Diagnosing neurodegenerative conditions called synucleinopathies, particularly in ...

SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment . SHANGH ...